Emtricitabine/tenofovir alafenamide

Drug Profile

Emtricitabine/tenofovir alafenamide

Alternative Names: DESCOVY; F/TAF; Tenofovir alafenamide/emtricitabine

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 04 May 2017 Registered for HIV-1 infections (Combination therapy, Treatment-experienced) in Canada (PO) before May 2017
  • 15 Dec 2016 Biomarkers information updated
  • 26 Oct 2016 Efficacy and adverse events data from the phase III Switch trial in HIV-1 infections presented at the Infectious Disease Week-2016 (IDW-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top